Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.

Autor:	Espy N; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Han X; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Grant S; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Kwara E; Division of Infectious Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Lakshminarayanan B; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Stirewalt M; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Seaton KE; Department of Surgery, Duke University, Durham, North Carolina, United States of America., Tomaras GD; Department of Surgery, Duke University, Durham, North Carolina, United States of America., Goecker E; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States of America., McElrath J; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States of America., Andriesen J; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Huang Y; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Department of Global Health, University of Washington, Seattle, Washington, United States of America., Walsh SR; Division of Infectious Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Hural J; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Jazyk:	angličtina
Zdroj:	PLOS global public health [PLOS Glob Public Health] 2023 Jun 08; Vol. 3 (6), pp. e0002037. Date of Electronic Publication: 2023 Jun 08 (Print Publication: 2023).
DOI:	10.1371/journal.pgph.0002037
Abstrakt:	Candidate HIV vaccines are designed to induce antibodies to various components of the HIV virus. An unintended result of these antibodies is that they may also be detected by commercial HIV diagnostic kits designed to detect an immune response to HIV acquisition. This phenomenon is known as Vaccine-Induced Seropositivity/Reactivity (VISP/R). In order to identify the vaccine characteristics associated with VISP/R, we collated the VISP/R results from 8,155 participants from 75 phase 1/2 studies and estimated the odds of VISP/R by multivariable logistic regression and 10-year estimated probability of persistence in relation to vaccine platform, HIV gag and envelope (env) gene inserts, and protein boost. Recipients of viral vectors, protein boosts, and combinations of DNA and viral-vectored vaccines had higher odds of VISP/R compared to those who received DNA-only vaccines (odds ratio, OR = 10.7, 9.1, 6.8, respectively, p<0.001). Recipients of gp140+ env gene insert (OR = 7.079, p<0.001) or gp120 env (OR = 1.508, p<0.001) had higher odds of VISP/R compared to those participants who received no env. Recipients of gp140 protein had higher odds of VISP/R than those that did not receive protein (OR = 25.155, p<0.001), and recipients of gp120 protein, had lower odds of VISP/R than those that did not receive protein (OR = 0.192, p<0.001). VISP/R persisted at 10 years in more recipients of env gene insert or protein compared to those who did not (64% vs 2%). The inclusion of gag gene in a vaccine regimen had modest effects on these odds and was confounded by other covariates. Participants receiving gp140+ gene insert or protein were most often reactive across all serologic HIV tests. Conclusions from this association analysis will provide insight into the possible impact of vaccine design on the HIV diagnostic landscape and vaccinated populations. Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: SRW is an Academic Editor at PLoS One; the authors declare no other competing interests. (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu